Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Research & Diagnostic Antibodies Receives Notice of Allowance for Sepsis Diagnostic Patent

Published: Thursday, August 09, 2012
Last Updated: Thursday, August 09, 2012
Bookmark and Share
Patent extends IP estate on plasma iNOS biomarker and covers iNOS immunoassays and apparatuses for early sepsis detection.

Research & Diagnostic Antibodies (R&D Antibodies) announced that it has received a Notice of Allowance from the Japan Patent Office for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology. Japanese Patent Application #2003-517204 covers very broadly the use of R&D Antibodies' immunoassays, assay kits, and apparatuses for the detection of plasma iNOS as an early biomarker for the prognosis and diagnosis of the life-threatening sepsis pathology. The JPO's Allowance extends R&D Antibodies' existing patent portfolio in this field (USA #6531578-B1 and 7198904-B1; European #EP1012605 and EP1412471; Japan #4117911; and Australian #2001280912 and 782922). Additional patent applications are pending.

Plasma iNOS is the foundation of R&D Antibodies' sepsis prognosis and monitoring tests that reveal very early the onset of the sepsis pathology. To date R&D Antibodies has conducted three clinical studies involving more than 295 ICU patients to demonstrate the utility of this new plasma biomarker. The last two clinical studies were partially funded by research grants awarded by the National Institutes of Health (NIH) after thorough peer review. R&D Antibodies is currently working on a $2.6 M grant awarded by the National Institute of General Medical Sciences to conduct a pivotal clinical study which should generate the data required to obtain FDA marketing clearance for this new blood test.

Plasma iNOS has been found to be a specific, accurate and reliable biomarker for detecting very early the onset of sepsis. This new test identifies those patients who will develop the sepsis pathology 24 - 48 hours prior to the appearance of the physiological symptoms currently used by physicians as indictors of the onset of sepsis. In a direct comparison with the Procalcitonin test (an FDA-approved test for sepsis), plasma iNOS was found to be more specific than PCT and to be an earlier biomarker for the onset of the sepsis pathology. Plasma iNOS as a biomarker was shown to predict accurately the onset of sepsis in more than 96% of the severely injured ICU patients studied.

"This patent continues to build our intellectual property estate and adds to our leadership position in the early detection of sepsis," said Dr. Robert Webber, Ph.D., President and CEO of R&D Antibodies, and the lead inventor on the patent. "Detection of circulating iNOS has broad application in numerous clinical settings including ICUs, emergency rooms, rehabilitation facilities, nursing homes, and outpatient clinics, and should guide physicians to initiate treatment earlier in this life-threatening pathology leading to reduced mortality and morbidity for the patient and reducing the huge financial drain that sepsis, severe sepsis and septic shock impose upon the healthcare system."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos